Drug Utilization and Cost Analysis Review of Anticancer Drugs Used in a Tertiary Care Teaching Hospital in South India

Abstract only Background: Cancer is ranked high among noncommunicable diseases and millions of people in India receive treatment of cancer every year. Aim: The current study aims to evaluate the trends and pattern of prescribing of anticancer drugs. The objectives of the study were to assess the rational use of anticancer drugs, to identify various types of cancer and to analyze the cost distribution of anticancer drugs. Methods: An observational, prospective study was conducted in 200 prescriptions in oncology department. Data were collected from case reports, prescriptions and medication charts in specially designed forms. Results: Out of 200 patients enrolled, majority were female (59.5%) and in the age group of 40-60 years (52%). Gastrointestinal tract cancers (25%) were most commonly observed, followed by breast cancer (18.5%) and genitourinary cancers (16.5%). Cisplatin (35%) was the most commonly prescribed anticancer drug, followed by paclitaxel (18.5%), carboplatin (14%), 5-fluorouracil (12.5%) and oxaliplatin (7.5%). Ranitidine, dexamethasone and ondansetron were used as palliative therapy either to prevent or manage the adverse reactions of the anticancer drugs. Trastuzumab contribute to the major cost (Rs. 450,000) in the drug therapy. The average cost of drug per prescription was Rs. 11,135. The overall prescribing indicators, point that the average number of total drugs, anticancer drugs and antibiotics were 12.22, 1.73 and 0.43 respectively. Conclusion: The usage of drugs was found to be rational and about 99.38% of the drugs used were from the hospital formulary. The prescribing habits are appropriate and are in accordance with WHO guidelines. The current study may support best prescribing practices to promote cost effective treatment and better health care delivery.